These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31436148)

  • 1. Natural Resistance of
    Carnielli JBT; Monti-Rocha R; Costa DL; Molina Sesana A; Pansini LNN; Segatto M; Mottram JC; Costa CHN; Carvalho SFG; Dietze R
    Am J Trop Med Hyg; 2019 Oct; 101(4):789-794. PubMed ID: 31436148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis.
    Carnielli JBT; Crouch K; Forrester S; Silva VC; Carvalho SFG; Damasceno JD; Brown E; Dickens NJ; Costa DL; Costa CHN; Dietze R; Jeffares DC; Mottram JC
    EBioMedicine; 2018 Oct; 36():83-91. PubMed ID: 30268832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil.
    Dos Santos Nogueira F; Avino VC; Galvis-Ovallos F; Pereira-Chioccola VL; Moreira MAB; Romariz APPL; Molla LM; Menz I
    Parasit Vectors; 2019 Feb; 12(1):79. PubMed ID: 30736866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes.
    Carnielli JB; de Andrade HM; Pires SF; Chapeaurouge AD; Perales J; Monti-Rocha R; Carvalho SF; Ribeiro LP; Dietze R; Figueiredo SG; Lemos EM
    J Proteomics; 2014 Aug; 108():198-208. PubMed ID: 24874972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
    Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates.
    Bhattacharya A; Ouellette M
    EBioMedicine; 2018 Nov; 37():13-14. PubMed ID: 30314891
    [No Abstract]   [Full Text] [Related]  

  • 8. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
    Reimão JQ; Pita Pedro DP; Coelho AC
    Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
    Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
    Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
    Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
    Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
    Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
    Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
    Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
    Gonçalves G; Campos MP; Gonçalves AS; Medeiros LCS; Figueiredo FB
    Parasit Vectors; 2021 Dec; 14(1):599. PubMed ID: 34886876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum.
    Hendrickx S; Mondelaers A; Eberhardt E; Lachaud L; Delputte P; Cos P; Maes L
    Parasitol Res; 2015 Jul; 114(7):2561-5. PubMed ID: 25877390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
    Pérez-Jacoiste Asín MA; Carrasco-Antón N; Fernández-Ruiz M; San Juan R; Alonso-Moralejo R; González E; Andrés A; López-Medrano F; Aguado JM
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27768239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
    Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
    Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
    Mbui J; Olobo J; Omollo R; Solomos A; Kip AE; Kirigi G; Sagaki P; Kimutai R; Were L; Omollo T; Egondi TW; Wasunna M; Alvar J; Dorlo TPC; Alves F
    Clin Infect Dis; 2019 Apr; 68(9):1530-1538. PubMed ID: 30188978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.